A topical antiviral liquid for treatment of viral warts, which is a multi-component formula that contains a number of acids and salts in an aqueous solution, which liquid has been shown to have superior effectiveness in completely penetrating and removing wart tissue, while encouraging rapid regeneration of healthy tissue.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

The present invention provides stable amorphous calcium carbonate (ACC) compositions, and food articles comprising said compositions.

Topical formulations of L-ascorbic acid dissolved in a combination of a sugar alcohol agent, and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, and have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.

A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.

Disclosed herein are compositions (e.g., sprays, paints, etc.) that comprise antimicrobial zeolite nanoparticles. Also provided are hemostatic compositions comprising zeolite nanoparticles, dryer sheets comprising zeolite nanoparticles, and textiles comprising zeolite nanoparticles. Also disclosed are compositions (e.g., sprays) that include a binder polymer to improve coating adherence. In some cases, the zeolite nanoparticles can further comprise an optical tracer (e.g., a fluorophore) associated with the zeolite nanoparticles. The optical tracer can be interrogated to confirm presence of the zeolite nanoparticles (or a coating comprising the zeolite nanoparticles) on a surface. Also provided are methods of forming viricidal coatings using compositions that comprise zeolite nanoparticles dispersed in a carrier.

Disclosed are compositions comprising a minced chorionic matrix, a homogenized amniotic matrix, and a homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising isolated, viable chorionic cells, a homogenized amniotic matrix, and a homogenized UC matrix, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising a minced chorionic matrix and a homogenized UC matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are compositions comprising isolated, viable chorionic cells and a homogenized

UC matrix, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

The present invention relates to a composition comprising 4-hexylresorcinol(4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The invention provides the use of mesenchymal stem cells for preparing drugs/medicines for the treatment of non-healing burn wounds. The inventor found that the mesenchymal stem cells of the present application are used to treat burn wounds and have significant curative effects. They can effectively promote the repair of hard-to-heal burn wounds, increase the healing rate of hard-to-heal burn wounds, and shorten wound healing time, with non-toxic side effects, easy absorption and other advantages. Therefore, the mesenchymal stem cells and the composition containing them can be used to prepare drugs/medicines for treating non-healing burn wounds.